论文部分内容阅读
目的探讨中药穴位药熨结合按摩在脑卒中后肩手综合征急性期治疗中的应用价值。方法选择2015年6月-2016年6月某院收治的60例脑卒中后肩手综合征急性期患者为研究对象,随机分为观察组和对照组各30例,对照组采用常规药物配合康复治疗,观察组在对照组治疗基础上采用中药穴位药熨结合按摩治疗,治疗4周后对两组患者的临床疗效及疼痛程度、上肢运动功能、日常生活活动能力进行对比分析。结果两组患者治疗前VAS评分、Fugl-Meyer评分及MBI评分差异均无统计学意义(P>0.05)。治疗4周后,两组VAS评分较治疗前明显减低,Fugl-Meyer评分及MBI评分均较治疗前明显升高,差异均有统计学意义(P<0.05或P<0.01),且观察组VAS评分明显低于对照组,Fugl-Meyer评分及MBI评分明显高于对照组,差异均有统计学意义(P<0.05)。观察组整体疗效及显效率均优于对照组,差异有统计学意义(P<0.05)。结论在常规药物及康复治疗基础上,采用中药药熨结合穴位按摩治疗脑卒中后肩手综合征能更好地改善患者疼痛症状及患肢运动功能,从而进一步提高临床疗效,值得临床推广。
Objective To investigate the value of traditional Chinese medicine acupoints combined with massage in the treatment of acute shoulder syndrome of shoulder after stroke. Methods Sixty patients with acute shoulder syndrome after stroke in our hospital from June 2015 to June 2016 were enrolled in this study. The patients were randomly divided into observation group (30 cases) and control group (30 cases). The control group was treated with conventional drugs After treatment for 4 weeks, the clinical efficacy, pain level, upper extremity motor function and activities of daily living in the two groups were compared and analyzed. Results There was no significant difference in VAS score, Fugl-Meyer score and MBI score between the two groups before treatment (P> 0.05). After 4 weeks of treatment, the VAS score of both groups was significantly lower than that before treatment, and the Fugl-Meyer score and MBI score were significantly higher than those before treatment (P <0.05 or P <0.01), and VAS The scores of Fugl-Meyer and MBI were significantly lower than those of the control group, with statistical significance (P <0.05). The overall efficacy and markedly effective rate in the observation group were better than those in the control group, with significant difference (P <0.05). Conclusion On the basis of conventional drugs and rehabilitation therapy, the use of Chinese herbal medicine combined with acupressure to treat post-stroke shoulder-hand syndrome can improve the pain symptom and motor function of limbs, so as to further improve the clinical efficacy and worthy of clinical promotion.